Literature DB >> 15527417

Expression and characterization of hepatitis B surface antigen in transgenic potato plants.

N Ya Shulga1, E B Rukavtsova, M A Krymsky, V N Borisova, V A Melnikov, V A Bykov, Ya I Buryanov.   

Abstract

Transgenic potato plants expressing the gene of hepatitis B surface antigen (HBsAg) under the control of the double promoter of 35S RNA of cauliflower mosaic virus (CaMV 35SS) and the promoter of patatin gene of potato tubers have been obtained. Biochemical analysis of the plants was performed. The amount of HBsAg in leaves, microtubers, and tubers of transgenic potatoes growing in vitro and in vivo was 0.005-0.035% of the total soluble protein. HBsAg content reached 1 microg/g in potato tubers and was maximal in plants expressing the HBsAg gene under the control of CaMV 35SS promoter. In transgenic plants expressing HBsAg gene under the control of tuber-specific patatin promoter, HBsAg was found only in microtubers and tubers and was absent in leaves. Western blot analysis of HBsAg eluted from immunoaffinity protein A-Sepharose matrix has been performed. The molecular weight of HBsAg peptide was approximately 24 kD, which is in agreement with the size of the major protein of the envelope of hepatitis B virus. Using gel filtration, it was determined that the product of HBsAg gene expression in potato plants is converted into high-molecular-weight multimeric particles. Therefore, as well as in recombinant HBsAg-yeast cells, assembling of HBsAg monomers into immunogenic aggregates takes place in HBsAg-transgenic potato, which can be used as a source of recombinant vaccine against hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527417     DOI: 10.1023/b:biry.0000046891.46282.c8

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  7 in total

1.  Agrobacterium-mediated transformation of yellow lupin to generate callus tissue producing HBV surface antigen in a long-term culture.

Authors:  Tomasz Pniewski; Józef Kapusta; Andrzej Płucienniczak
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

2.  Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation.

Authors:  Tomasz Pniewski; Józef Kapusta; Piotr Bociąg; Jacek Wojciechowicz; Anna Kostrzak; Michał Gdula; Olga Fedorowicz-Strońska; Piotr Wójcik; Halina Otta; Sławomir Samardakiewicz; Bogdan Wolko; Andrzej Płucienniczak
Journal:  J Appl Genet       Date:  2010-11-23       Impact factor: 3.240

3.  Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus.

Authors:  Choonghee Lee; Hyung-Hwan Kim; Kyung Mi Choi; Kyung Won Chung; Yien Kyoung Choi; Mi Jung Jang; Tong-Soo Kim; Nam-Jun Chung; Ho-Gun Rhie; Ho-Sa Lee; Youngjoo Sohn; Hyuck Kim; Sung-Jae Lee; Hyeong-Woo Lee
Journal:  Malar J       Date:  2011-04-29       Impact factor: 2.979

4.  Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation.

Authors:  Tomasz Pniewski; Józef Kapusta; Piotr Bociąg; Anna Kostrzak; Olga Fedorowicz-Strońska; Marcin Czyż; Michał Gdula; Paweł Krajewski; Bogdan Wolko; Andrzej Płucienniczak
Journal:  Plant Cell Rep       Date:  2012-01-14       Impact factor: 4.570

Review 5.  The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects?

Authors:  Tomasz Pniewski
Journal:  Int J Mol Sci       Date:  2013-01-21       Impact factor: 5.923

Review 6.  The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.

Authors:  Young Hee Joung; Se Hee Park; Ki-Beom Moon; Jae-Heung Jeon; Hye-Sun Cho; Hyun-Soon Kim
Journal:  Int J Mol Sci       Date:  2016-10-13       Impact factor: 5.923

Review 7.  Plants as bioreactors: Recent developments and emerging opportunities.

Authors:  Arun K Sharma; Manoj K Sharma
Journal:  Biotechnol Adv       Date:  2009-06-30       Impact factor: 14.227

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.